Abstract:e24119 Background: Current guidelines recommend prophylactic use of granulocyte colony-stimulating factor (G-CSF) to reduce the incidence, duration, and severity of chemotherapy-induced neutropenia. We evaluated the efficacy and safety of mecapegfilgrastim, a long-acting G-CSF, in preventing neutropenia for solid tumor patients during concurrent chemoradiotherapy (CCRT). Methods: In this multicenter, open-label, randomized controlled trial, patients with lung, esophageal, or cervical cancers, and an ECOG performance status of 0-2 were randomized 1:1 to the study or control group. Both groups received standard CCRT with two 21-day cycles of taxanes and platinum-based chemotherapy. In the study group, mecapegfilgrastim 6 mg was administered 24 hours after chemotherapy for each cycle, whereas the control group received no prophylaxis for neutropenia. Short-acting G-CSF was administered if neutrophil counts fell below 2.0×10^9/L. Treatment-emergent adverse events (TEAEs) were monitored for 2 cycles and graded per CTCAE v5.0. The primary endpoint was the incidence of grade 3/4 neutropenia during CCRT. Results: From Apr 2022 to Dec 2023, 97 patients were enrolled: 48 in the study group and 49 in the control group. The median age was 59 years (range 51-71) in the study group and 60 years (range 34-71) in the control group. Baseline characteristics were balanced between two groups. Eleven patients (22.9%) in the study group experienced grade 3/4 neutropenia, compared to 27 (55.1%) in the control group (nominal p= 0.002). Three patients (6.3%) in the study group and 2 (4.1%) in the control group developed febrile neutropenia (FN). For 18 lung cancer patients, none of the study group experienced grade 3/4 neutropenia, while 2 patients (25.0%) in the control group did. FN was not reported in either group. Among 40 esophageal cancer patients , grade 3/4 neutropenia was observed in 4 patients (21.1%) of the study group, compared to 12 (57.1%) of the control group, with one case of FN in each group. For 39 gynecological cancer patients, grade 3/4 neutropenia occurred in 7 patients (36.8%) in the study group and 13 (65.0%) in the control group. Two patients of the study group and 1 of the control group developed FN. Short-acting G-CSF was required in 18 patients (37.5%) of the study group and 33 (67.4%) of the control group. TEAEs were reported in 27 patients (56.3%) of the study group and 41 (83.7%) of the control group. Notably, grade ≥3 TEAEs were reported in 21 patients (43.8%) of the study group and 30 (61.2%) of the control group, maily including hematologic toxicities like neutropenia, thrombocytopenia, and lymphocytopenia. Serious TEAEs were reported in 1 patient (2.1%) of the study group and 2 (4.1%) of the control group. One patient (2.1%) in the study group discontinued treatment due to TEAEs. Conclusions: Prophylaxis with mecapegfilgrastim reduced the incidence of grade 3/4 neutropenia during CCRT, with good safety. Clinical trial information: ChiCTR2200058551.

Evaluation of the Quality of Life and Economic Burden with Granulocyte-Colony Stimulating Factor in Chinese Breast Cancer Patients Receiving Docetaxel, Epirubicin and Cyclophosphamide

Cost-Effectiveness Analysis of PEG-rhG-CSF as Primary Prophylaxis to Chemotherapy-Induced Neutropenia in Women With Breast Cancer in China: Results Based on Real-World Data

A Multicenter, Prospective, Non-Interventional Real-World Study to Assess the Effectiveness of Mecapegfilgrastim in Preventing Neutropenia in Patients with Gastrointestinal Cancer.

White Blood Cell Kinetics in Patients with Gynecologic Cancer Receiving Mecapegfilgrastim Prophylaxis: A Multicenter Real-World Study.

Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan

Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients

A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF)

Advantages of Prophylactic PEG-rhG-CSF Versus Rhg-Csf in Breast Cancer Patients Receiving Multiple Cycles of Myelosuppressive Chemotherapy: an Open-Label, Randomized, Multicenter Phase Ⅲ Study.

The Efficacy Research of Prophylactic PEG-rhG-CSF in Preventing Neutropenia in Early-Stage Breast Cancer Patients Treated with Docetaxel-Based Chemotherapy: A Retrospective Analysis

Effect of Granulocyte Colony-Stimulating Factor As Prophylaxis on Adjuvant Chemotherapy-Induced Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Epirubicin and Cyclophosphamide

The Role of Prophylactic Application of Granulocyte Colony Stimulating Factor in Adjuvant Chemotherapy for Epithelial Ovarian Cancer

Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial

[The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving adjuvant chemotherapy]

Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer

Real-world study of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal tumors

Febrile Neutropenia and Its Associated Hospitalization in Breast Cancer Patients on Docetaxel-Containing Regimen: A Retrospective Cohort Study on Duration of Prophylactic GCSF Administration

Efficacy and Safety of Mecapegfilgrastim in Preventing Neutropenia During Concurrent Chemoradiotherapy.

[Treatment of Chemotherapy-Induced Neutropenia Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor: a Multi-Center Randomized Controlled Phase II Clinical Study].

Safety and Efficacy of PEG-rhG-CSF As Primary Prophylaxis Against Neutropenia Induced by Combination Chemotherapy Regimens Involving Oral Chemotherapy Agents in Gastrointestinal Cancer Patients: A Prospective, Exploratory, Non-Randomized Controlled Study.

Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients

Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer